Paediatric psychopharmacology: Closing the gap between science and practice

Expert Opinion on Pharmacotherapy

Volumn 2, Issue 4, 2001, Pages 523-525

  Findling, R L ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Adolescents; Autistic disorder; Bipolar disorder; Children; Psychopharmacology

Indexed keywords

LITHIUM; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT; RISPERIDONE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROATE SEMISODIUM;

ADOLESCENT; ADULT; AUTISM; CHILD; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DRUG EFFICACY; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LIFE CYCLE; MANIC DEPRESSIVE PSYCHOSIS; ONSET AGE; PEDIATRICS; PSYCHOPHARMACOLOGY; PSYCHOSOCIAL CARE; SCHIZOPHRENIA; ARTICLE; BIPOLAR DISORDER;

ADOLESCENT; AUTISTIC DISORDER; BIPOLAR DISORDER; CHILD; HUMAN; PEDIATRICS; PSYCHOPHARMACOLOGY;

EID: 0035004168     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2.4.523     Document Type: Editorial

References (8)

1. The pharmacological treatment of depression in children and adolescents
2. Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance
3. Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes
4. Special issues in the treatment of paediatric bipolar disorder
5. Pharmacotherapeutic management of autism
6. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network: Background and rationale for an initial controlled study of risperidone
7. The rationale, design and progress of two novel maintenance treatment studies in pediatric bipolarity
8. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder